KEY POINTSAnnual growth in the number of kidney transplants began to accelerate in 2019.
Economic Impact Analysis
Reports
Displaying 1 - 10 of 36. 10 per page. Page 1.
Advanced SearchReport
Market Forces in Medicare Reimbursement: Traditional Medicare, Medicare Advantage, and Provider Resource Constraints
EXECUTIVE SUMMARYMedicare reimbursement is administered, but it is not insulated from markets for provider labor, capital, facilities, and technology. Traditional Medicare payment formulas incorporate market-basket input prices, geographic wage indexes, case mix, and quality adjustments; total spending also depends on utilization.
Report
Quantifying the Value of Consumer Choice: A Foundation for Regulatory Impact Analysis and Beyond
Executive SummaryRegulations often restrict the range of market choices available to consumers, yet they are promulgated without a quantitative analysis of that cost—a fundamental flaw in regulatory impact analysis. This paper fills the gap by supplying a portable choice-value factor.
Report
An Overview of State-Directed Payments and Medicaid Provider Taxes: History and Potential Effects of the Working Families Tax Cut Legislation on Health Care Costs
Health care provider taxes and state-directed payment policies in the Working Families and Tax Cut legislation are expected to reduce non-Medicaid prices by up to 3.5 percent in markets with provider taxes and reduce spending on Medicaid, commercial and Medicare coverage.
ASPE Data Point
HHS Standard Values for Regulatory Analysis
The U.S. Department of Health and Human Services (HHS) analyzes the benefits, costs, and other impacts of significant proposed and final rulemakings, consistent with the requirements of several executive orders and statutes. HHS develops these analyses according to technical guidance published by the U.S.
ASPE Issue Brief
Drug Competition Series: Analysis of New Generic Markets Effect of Market Entry on Generic Drug Prices: Medicare Data 2007-2022
The U.S. has a number of policies related to drug pricing, affordability, and availability. To encourage manufacturers to innovate with new therapies, patent policy rewards the creation of new branded medicines. As those patents come to an end, generic drug manufacturers may enter a market and seek to sell their products at lower prices than the competing brand drugs.
Report
Guidance on Proper Consideration of Small Entities in Rulemakings of the U.S. Department of Health and Human Services
This guidance, originally published in 2003, contains the following introduction:
ASPE Issue Brief
Medicaid: The Health and Economic Benefits of Expanding Eligibility
This Issue Brief examines the impact of Medicaid throughout its six decades and highlights the importance of Medicaid coverage for low-income children and adults. The brief reviews studies showing that access to Medicaid coverage is associated with a significant improvement in health and mortality.
Report
Competition in Prescription Drug Markets, 2017-2022
The cornerstone of a well-functioning market is competition. President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” identified a lack of competition as a key driver for problems across economic sectors.